Levi & Korsinsky notifies investors that it has commenced an investigation into Legend Biotech Corporation (NASDAQ: LEGN) concerning potential violations of the federal securities laws.
On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility. Legend also detailed its struggles with improving manufacturing turnaround times, as well as concerns surrounding the US and non-US price differentials and its ability to penetrate the community settings for its pharmaceutical treatments. Analysts responded to the news with lowered price targets. Following this news, Legend’s stock price fell over 10% to close at $27.80 per share on May 14, 2025.
If you suffered a loss on your Legend Biotech Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





